Bliss Aesthetics announced it raised $17.5 million in a seed funding round to grow its artificial intelligence (AI)-powered platform that connects patients with board-certified plastic surgeons. 

Shine Capital led the financing, followed by Synchrony Ventures, Sheva Ventures, Point72 Ventures, and Cerca Partners.

Using GenAI, Stable Diffusion, and computer vision models, Bliss’ platform is designed to visualize patients’ cosmetic enhancements and match the patient with a board-certified physician. The platform also provides information about potential financing partners to create a seamless experience. Further, the platform improves conversion rates by up to 40%, according to a release from Bliss Aesthetics. 

“This funding will give us the ability to harness the momentum we are experiencing, building on the 500% growth of our provider base in our patient-to-physician app since our launch while expanding to five new states across the country,” says Gal Yosef, Bliss’ co-founder and CEO, in a release. “By combining intelligent matchmaking with AI tools, we equip patients to make informed, confident, and financially savvy decisions and give doctors the ability to deliver better outcomes to more patients with less administrative burden.”

Celebrity doctor and board-certified plastic surgeon Michael Salzhauer, MD, who co-founded the platform and serves as chief medical officer, adds in a release, “Through working firsthand in the industry, I’ve seen the need for a seamless consumer platform like Bliss. For physicians, the next-generation platform streamlines patient management and positions surgeons to deliver more precise patient outcomes and improve satisfaction.”

Mo Koyfman, founder and general partner at Shine Capital, adds in a release, “We love investing in areas undergoing a radical shift in consumer perceptions and behavior. Cosmetic surgery is an area driven by demographics, and building technology tools to serve patients and providers helps the market develop while ensuring the highest-quality experience.”

The Bliss Aesthetics platform is available to patients across Florida, Texas, Illinois, Arizona, Michigan, and North Carolina.

ID 349550023 © Roman Samborskyi | Dreamstime.com

Related Read:

JOYA Health, a corporate skin health benefit provider, has announced a new integration with Aesthetic Record, an electronic medical record (EMR) and practice management platform used by over 9,000 aesthetic clinics. The collaboration allows clinics to redeem JOYA Health membership benefits directly at point of sale (POS) within Aesthetic Record’s system.

Operational and Financial Integration

The integration supports real-time patient benefit redemptions and tracks financial data, aiming to improve practice efficiency and patient experience. Clinics using both platforms can now eliminate manual processes and gain a consolidated view of patient interactions and revenue.

Patient Access and Acquisition

JOYA Health functions as an employer-sponsored benefit, offering services such as skin cancer screenings, acne and anti-aging treatments, and hair loss care. With this integration, JOYA members can access participating clinics more easily and receive personalized treatment plans at reduced out-of-pocket costs.

Industry Perspective

JOYA Health’s VP of Product, Ian Metz, described the integration as a step toward improving both operational efficiency and patient experience. Tiphany Hall, Chief Growth Officer at Aesthetic Record, noted that the partnership also serves to credential providers within JOYA’s network, potentially enhancing lead generation for participating clinics.

Getting Started

• Existing Users: Aesthetic Record clinics already partnered with JOYA can activate the integration via the AR Wallet for immediate access to benefit redemptions and financial tracking.
• New Clinics: Aesthetic Record users not yet on JOYA’s network are invited to join and secure regional access.

Photo: ID 130810908 © Funtap P | Dreamstime.com

BioLab Holdings Inc, a Phoenix-based medical manufacturer specializing in wound healing and wound care products, announced the establishment of its Medical Advisory Board, composed of wound care specialists dedicated to advancing patient care and clinical excellence. This group of experts will provide insights and guidance across various aspects of the company’s operations.

Board to Offer Multidisciplinary Clinical Expertise

The board members represent a diverse range of medical specialties, including primary care, plastic surgery, podiatry, and dermatology. The company says that this group of physicians, who have extensive frontline experience in wound care, bring a wealth of clinical knowledge that will support Biolab Holdings in its pursuit of becoming a global leader in the field—while ultimately prioritizing the well-being of patients. The medical board reportedly will enhance BioLab’s research and development, distribution training, peer-to-peer engagement, clinician education, and patient-centered care. 

Leadership Emphasizes Board’s Role in Expanding Access to Care

“We are honored to welcome these esteemed physicians to our organization,” said Dr Marshall Medley, chief medical officer at BioLab. “Their expertise and passion for wound care will be instrumental in furthering the work we are all passionate about—improving access to care and healing patient’s wounds.”

Dr Krishna Narayanan Joins Advisory Board

Pittsburgh-based plastic surgeon Krishna Narayanan, MD, will be a member of the Medical Advisory Board. With over 25 years of experience in private practice, he earned his medical degree from the University of Madras, Chennai, India, in 1981 and completed a Plastic Surgery Fellowship at UPMC in Pittsburgh in 1994.

Experience in Advanced Wound Healing Techniques

Narayanan specializes in wound care management and surgical interventions including split thickness skin graft and PRP placement for wound healing, amniotic allograft with stem cell stimulation, collagen matrix graft and more.

Leadership Roles in Hospital-Based Wound Care Programs

He holds hospital privileges at multiple Pennsylvania institutions and serves as medical director and executive committee member at Encompass, Select Specialty, and PAM Health Hospitals. He also serves as the medical director of wound care to oversee clinical methods and outcomes to treat patients with complex wound care problems.

Photo: BioLab Sciences

Establishment Labs Holdings Inc, a global medical technology company focused on breast aesthetics and reconstruction, announced a partnership with GRAMMY Award-winning singer Meghan Trainor. Trainor recently received Motiva Implants.

Trainor Shares Her Experience with Motiva Implants

“Self-confidence and body positivity are so important to me. After losing a bunch of weight and having two kids, I have always struggled loving my breasts because they were never even. I’ve been dreaming about getting this done for so many years. Once I learned about the recent FDA approval of Motiva Implants, I knew this was the perfect time for me,” Trainor said. “I did my research, consulted with several plastic surgeons, and chose Motiva Implants because they offered the look, the smooth silk feel, and the safety I was looking for. There is just such a difference with these new generation implants. I’m absolutely in love with the results—they feel so soft and natural and I’m more confident than ever. I can’t wait to get back on stage with so many new outfit choices.”

Motiva Implants: Design and Features

Motiva Implants, available to patients in the United States since October 2024, feature the patented SmoothSilk surface, which is reportedly designed for enhanced biocompatibility and scientifically shown to promote low inflammation. According to the company, this surface not only helps the tissue around the implant to stay soft, but also has led to an industry-low 0.5% capsular contracture rate.

Motiva SmoothSilk Ergonomix implants feature a unique shape that adapts as the body changes position, maintaining a round shape when lying down and a teardrop shape when standing up. Motiva SmoothSilk Round implants provide increased upper breast fullness and softness while keeping a round full form regardless of position.

Clinical Studies and Patient Satisfaction

Motiva devices, through FDA clinical studies, have reported less than 1% device-related complications and above 97% patient and surgeon satisfaction rates, according to the company.

Establishment Labs on the Partnership

“We could not be more thrilled to partner with Meghan Trainor, an artist who echoes the sentiments we hear from millions of women around the world who choose Motiva for their breast augmentation,” commented Juan José Chacón-Quirós, founder of Establishment Labs. “It is an exciting time for the organization as we are finally able to bring Motiva to women in the United States. These implants were designed to ensure women’s health and well-being. Motiva enables plastic surgeons to perform the surgeries they want and women to get the results they deserve. This is real innovation leading to better patient outcomes. Top plastic surgeons around the US are adopting Motiva Implants rapidly, and many women, like Meghan, are choosing and embracing both the technology and the natural results.”

Motiva’s Global Presence and Scientific Backing

Since first becoming commercially available in 2010, over 4 million Motiva devices have been delivered to plastic and reconstructive surgeons in over 90 countries globally, according to Establishment Labs. The company’s technologies and products are covered by over 200 patent applications in 20 separate patent families worldwide and are supported by over 100 clinical and scientific studies and peer-reviewed publications.

Plastic Surgeon on the Benefits of Motiva Implants

“When Meghan came to me, I was excited to offer her Motiva Implants. These implants are so much better than anything that has been available on the US market. They are designed not only to achieve my patients’ aesthetic goals but also to ensure the highest quality and safety, backed by years of research and scientific data that show some of the lowest complication rates,” said Payman Danielpour, MD, a board-certified plastic surgeon in Beverly Hills, Calif. “Since their approval, I’ve been using Motiva Implants almost exclusively and couldn’t be more pleased with the results. Motiva is a new generation of implants and I’m thrilled that Meghan, and women across the US, now have access to such an advanced device. I’ve already seen their incredible impact on many patients in my practice.”

Photo: Establishment Labs

Craniofacial plastic and reconstructive surgeon George Kamel, MD, has been appointed surgical director of the pediatric craniofacial and plastic surgery program at Joe DiMaggio Children’s Hospital, located in Hollywood, Fla.

Overseeing Surgical Care for Complex Craniofacial Conditions

Kamel, a board-certified plastic surgeon, will oversee the surgical program, advancing specialized care for children with complex craniofacial conditions. Joe DiMaggio Children’s Hospital delivers surgical care to young patients facing congenital anomalies, facial trauma, and other craniofacial disorders.

Commitment to Pediatric Patients and Families

“I am honored to join Joe DiMaggio Children’s Hospital in this pivotal role,” said Kamel. “My passion lies in helping children lead healthy, confident lives through advanced surgical techniques. I look forward to collaborating with the exceptional team here to provide the highest standard of care for our young patients and their families.”

Continued Work in Private Practice

Kamel is also in private practice at GK Plastic Surgery, located in Fort Lauderdale, Fla.

Photo: ID 90815937 © Sudok1 | Dreamstime.com

XOD Aesthetics on Demand, a provider of mobile aesthetic solutions, announced Bertha Baum, MD, a dermatologist and cosmetic surgeon, as its first clinical excellence leader. In addition, the firm welcomed Terri Ross and Brandon James Thompson to its advisory board.

“These top aesthetic industry leaders bring unparalleled expertise both clinically and in sales, business strategy, and practice management, reinforcing XOD’s mission to revolutionize the aesthetics industry through accessibility, portability, and innovation,” says Lee Haimoff, CEO and founder of XOD in a release.

Baum, a board-certified dermatologist and cosmetic surgeon based in Florida, is recognized for her expertise in skincare, cosmetic dermatology, and laser technologies. She has contributed to numerous scientific publications and remains involved in dermatological organizations. 

“I’m looking forward to being a part of XOD’s clinical excellence leaders and bringing my expertise in developing the next generation of energy-based devices. We’re also thrilled to be the first dermatology office in Florida to offer Breeze & WonderTouch devices in our clinic,” she says in a release.

Advisory Board Additions

Terri Ross is a thought leader in practice management and high-performance sales coaching, with over 15 years in the medical aesthetics sector. As the founder and CEO of Terri Ross Consulting, she has helped scale aesthetic practices through strategic development and training. Having led national sales teams for Fortune 500 companies and co-founded the 4S Summit, Ross is passionate about driving industry growth.

“XOD is setting a new standard in aesthetics by providing practitioners with transparent, accessible, and high-performance solutions to scale their businesses beyond the traditional brick and mortar,” says Ross in a release. “I’m thrilled to be part of a company that prioritizes both innovation and customer success. Together, we will help aesthetic professionals thrive in an ever-evolving landscape.”

Brandon James Thompson, a 25-year veteran in sales and management, has built a career spanning orthopedics, dental, dermatology, and aesthetics. He has held roles at industry giants like Syneron and Cutera before launching Careers in Aesthetics, a recruiting firm dedicated to the industry. He has experience in building sales teams, raising capital, and launching startups.

“I am honored to join XOD’s advisory board and support a company that is truly disrupting the aesthetic industry,” says Thompson in a release. “Their focus on business scalability aligns perfectly with the needs of today’s providers. I look forward to contributing my experience to help XOD expand its impact.”

Photo caption: Bertha Baum

Photo credit: XOD Aesthetics on Demand

Rejuran announced a partnership with aesthetic dermatology provider LaserAway to bring South Korea’s skin booster technology to the United States. Now, LaserAway will help drive Rejuran’s first major US market entry, introducing its salmon DNA-based treatments nationwide.

The partnership introduces two innovative Rejuran bioregenerator treatments: Healing Essence and Tone-Up Booster. Unlike traditional biostimulators, these next-generation bioregenerators utilize pharmaceutical-grade hydrolyzed salmon DNA technology through a patented DNA optimization technology. This approach is designed to enhance results from LaserAway’s laser resurfacing and radiofrequency microneedling treatments by supporting natural skin renewal at a deeper level.

“This partnership represents a significant milestone in bringing advanced Korean skincare innovation to the US market,” says Daniel Choi, CEO at Rejuran, in a release. “LaserAway’s rapid emergence as our leading US provider, combined with their expertise in aesthetic treatments and national reputation for excellence, makes them the ideal partner to introduce this proven technology in the US.”

The treatments feature Rejuran’s proprietary hydrolyzed salmon DNA technology, which shares 97% genetic similarity with human DNA, designed to enable superior skin penetration and rejuvenation, without adverse effects. The Healing Essence contains 2.0% hydrolyzed DNA for optimal post-procedure recovery with improved hydration, skin texture, and wrinkle reduction, while the Tone-Up Booster combines 1.0% hydrolyzed DNA with skin brighteners such as tranexamic and ascorbic acids and glutathione for enhanced skin tone improvement.

“By bringing Rejuran’s innovative DNA technology to our clinics, we’re offering our clients access to one of South Korea’s most sought-after skin treatments,” says Scott Heckmann, CEO of LaserAway, in a release. “This partnership aligns perfectly with our mission to provide the most advanced aesthetic treatments while maintaining the highest standards of safety and efficacy.”

Summary:

LaserAway has partnered with Rejuran to introduce Korean salmon DNA-based skin boosters to the US aesthetic market. The treatments, Healing Essence and Tone-Up Booster, are designed to enhance the effects of microneedling and laser resurfacing by promoting deeper skin renewal. Unlike traditional biostimulators, these bioregenerators use hydrolyzed salmon DNA technology to improve skin hydration, texture, and tone. The collaboration marks Rejuran’s first major expansion into the U.S., with LaserAway serving as its primary provider.

Key Takeaways:

• Korean Salmon DNA Skin Boosters Enter U.S. Market – LaserAway is introducing Rejuran’s bioregenerator treatments, which support skin renewal after microneedling and laser procedures.
• Technology Focuses on Deeper Skin Repair – The hydrolyzed salmon DNA-based treatments aim to improve hydration, texture, and tone without the risks associated with traditional biostimulators.

Photo caption: Healing Essence

Photo credit: Rejuran

XOD Aesthetics on Demand, a provider of advanced aesthetic devices designed for mobility and business scalability, announced that Izhak Musli has joined its advisory board. Musli, a thought leader in practice management, business operations, and technology-driven efficiency, will support XOD’s mission to improve the aesthetics industry by providing solutions that enhance accessibility, affordability, and patient experience.

Musli brings more than 17 years of leadership experience in the aesthetics and technology industries. As the founder of AtlasKPI and MedicalPRM, two business intelligence and lead management platforms that have since been acquired, he has played a role in optimizing operational efficiencies for aesthetic practices. 

His tenure as co-CEO of APX Platform and senior vice president at Engage Technologies Group provided further experience in data analytics, financial strategy, and practice optimization.

“We are thrilled to welcome Izhak to our advisory board,” says Lee Haimoff, co-founder and CEO of Aesthetics on Demand, in a release. “His extensive background in business intelligence and practice management aligns perfectly with our mission to empower aesthetic providers with innovative, portable, and cost-effective solutions. Izhak’s insights will be invaluable as we continue to challenge outdated business models and set a new standard for transparency, accessibility, and superior patient experiences.”

XOD offers compact devices that cater to a variety of treatments, from laser hair removal to skin rejuvenation. The company’s emphasis on portability aims to enable providers to expand their reach through mobile services, concierge treatments, and multi-location flexibility.

“I am honored to join the Advisory Board at XOD, a company that is truly redefining the aesthetic industry. Their commitment to transparency, innovation, and customer empowerment resonates deeply with my own values,” says Musli in a release. “I look forward to leveraging my experience to help XOD grow and continue delivering unparalleled solutions to aesthetic providers worldwide.”

Summary:

XOD Aesthetics on Demand, a company specializing in portable aesthetic devices, has expanded its advisory board by bringing on Izhak Musli, who has experience in practice management, business strategy, and technology-driven efficiency. The new advisor has a background in data analytics, financial strategy, and operational optimization for aesthetic practices, having previously founded and led companies focused on business intelligence and lead management. XOD aims to use this expertise to enhance accessibility, affordability, and scalability in the aesthetics industry, particularly through its mobile service model that allows providers greater flexibility in offering treatments.

Key Takeaways:

1. XOD Aesthetics on Demand Adds Industry Expertise – The company has expanded its advisory board with a specialist in practice management and business intelligence to support growth and innovation.
2. Focus on Mobile and Scalable Aesthetic Solutions – XOD provides portable aesthetic devices designed to enable concierge treatments, mobile services, and multi-location flexibility
3. Commitment to Industry Innovation – The company aims to challenge traditional aesthetic business models by promoting transparency, affordability, and efficiency through technology-driven solutions.

Photo caption: SILKRO RF Microneedling & Plasma Technology Integrated Solution

Photo credit: XOD Aesthetics on Demand

Key Takeaways:

• Facelifts, particularly deep plane techniques, are surging in popularity as patients seek natural-looking rejuvenation with minimal downtime.
• The demand for body contouring procedures is rising, driven by an increase in GLP-1-induced weight loss and the need for skin-tightening solutions.

RealSelf, the online resource for people exploring cosmetic treatments and providers, released its quarterly Real Talk report offering a comprehensive look at the key trends shaping the aesthetics landscape for Spring 2025. The report features industry insights from top physicians across the United States, including Dr Urmen Desai, Dr Suzette Miranda, Dr Goretti Ho Taghva, and Dr Jill Hessler.

Based on insights from over 55 million site visits, the Real Talk report presents predictions in the aesthetic industry designed to inform consumers’ decisions. Top trends and key takeaways include:

• Surgical Facial Optimization: Facelifts will be the most popular this spring. People are seeking more surgical interventions for the face and seeking a more natural look. Modern techniques such as the preservation of deep plane facelift allows for a natural rejuvenation that reduces the signs of aging while preserving the patient’s identity, with less downtime and recovery than traditional facelift techniques.
• The Internal Bra: Patients will increasingly choose to opt into this type of breast scaffolding during breast augmentation or reconstruction procedures due to its ability to provide enhanced support and improve the long-term stability of implants. The internal bra, typically made of surgical mesh or similar materials, helps to prevent implants from dropping or shifting over time, offering a more secure, perkier, natural shaped breast.
• Body Contouring: As we near the summer months, we will see a rise in demand for body contouring procedures like body lifts, brachioplasties (arm lifts), and thigh lifts. This likely rise in demand can be linked to an increase in GLP-1 type medications as rapid weight loss often leaves the skin lacking elasticity, creating the need for treatments that restore shape and firmness.
• Refreshed and Defined Eyelids: Upper and lower blepharoplasty across all groups, including more male patients will become increasingly popular. Many will seek a refreshing, well-rested appearance without altering the natural eye shape. Upper blepharoplasty will especially be popular among women who are mindful of evolving makeup trends that emphasize a defined eyelid contour.
• Regenerative Treatments: There will be a renewed interest in classic treatments, as regenerative treatments are the future of aesthetics. More patients will prioritize medical facials, microneedling, BBL Moxi, Therage FLX, Ultherapy Prime to enhance skin texture and elasticity, reflecting a more holistic and long-term approach to facial rejuvenation. With beloved treatments like the Vampire Facial, that combines dermal fillers with PRP, and new techniques like AutoCorre, patients can expect a completely natural facial rejuvenation.

“In a world where the notion of beauty is always changing, understanding and anticipating trends to help inform aesthetic decisions for the average consumer is key,” said Minou Clark, CEO of RealSelf. “As a legacy brand, it’s important we stay one step ahead and are at the forefront of driving change in the industry as we work to further destigmatize cosmetic procedures.”

Photo: ID 67602074 | Aesthetic © Vchalup | Dreamstime.com

Summary:
Crown Laboratories has acquired Revance Therapeutics, adding Daxxify, an injectable wrinkle treatment, and the RHA Collection of dermal fillers to its portfolio. Revance’s common stock will be delisted from NASDAQ as part of the transaction. The companies announced the merger agreement last August. The acquisition expands Crown’s portfolio, which includes aesthetic and skincare brands such as SkinPen, PanOxyl, Blue Lizard, and StriVectin. Crown will continue Revance’s partnership with Teoxane SA for the US distribution of RHA dermal fillers.

Key Takeaways:

• Crown Acquires Revance – The acquisition adds Daxxify and the RHA Collection to Crown Laboratories’ offerings.
• Revance Stock Delisted – Revance’s common stock will be removed from NASDAQ and deregistered under federal securities regulations.
• Business Operations Remain Unchanged – Crown will continue Revance’s partnership with Teoxane SA for US distribution of dermal fillers.

Crown Laboratories Inc, a privately held global skincare company, has acquired Revance Therapeutics Inc, a biotechnology company specializing in aesthetic and therapeutic offerings whose portfolio includes Daxxify for injection and the RHA Collection of dermal fillers. 

RHA technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance is an independent distributor of Teoxane SA for the RHA Collection of dermal fillers for US distribution. Revance had also partnered with Viatris Inc to develop a biosimilar to onabotulinumtoxinA, commonly known as Botox, for injection and Shanghai Fosun Pharmaceutical to commercialize Daxxify in China.

“We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics—relax, restore, and regenerate—and we will support these offerings with a highly trained and experienced sales force,” says Jeff Bedard, founder and chief executive officer of Crown, in a release. “We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”

Acquisition Brings Together Aesthetic and Skincare Brands

The companies announced they entered into a merger agreement last August, stating that the combination would provide an opportunity to create “a leading, innovative, high-growth aesthetics and skincare company,” with the combined company’s brands including Daxxify (toxin), the RHA Collection (filler), SkinPen (microneedling), PanOxyl (acne), Blue Lizard (sunscreen), and StriVectin (anti-aging).

According to a statement on Revance’s website, “The newly combined portfolio allows you, our practice partners, to achieve dynamic results and drive high patient satisfaction, growing your business through our differentiated brands and unwavering support.” The statement notes that all processes, support, and representation for each company remain the same until further notice. “We commit to clear communication and providing support throughout this process and will share more details as we have more information to share,” the statement reads.

Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.

“We are thrilled to celebrate the successful completion of this transaction and to commence the integration of two innovative companies that we believe will create a leading player in the dynamic skincare and aesthetics markets,” says co-founders and managing partners Andrew Goldman and David Solomon of Hildred Capital, Crown’s parent company. “Crown remains committed to providing healthcare providers and aesthetic practices with outstanding science-based products. We are excited to bring together Revance’s and Crown’s aesthetic offerings, and we look forward to continuing Revance’s relationship with Teoxane to grow the RHA Collection by Teoxane in the US market.”

ID 60933364 | Acquisition © Pichetw | Dreamstime.com